Skip to main content

Advertisement

SpringerLink
Log in

Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022

  • Special Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Chronic kidney disease (CKD) is one of the most disabling disorders with significant comorbidity and mortality. Incidence and prevalence of CKD in cancer survivors are remarkably high in both adults and pediatric patients. The reasons for this high incidence/prevalence are multifold but kidney damage by cancer itself and cancer treatment (pharmacotherapy/surgery/radiation) are the main reasons. Since cancer survivors commonly have significant comorbidities, risk of cancer recurrence, limited physical function or life expectancy, special attentions should be paid when considering the treatment of CKD and its complications. Especially, shared decision-making should be considered when selecting the renal replacement therapies with as much information/facts/evidence as possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mayer DK, Nasso SF, Earp JA (2017) Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA. Lancet Oncol 18:e11–e18

    Article  PubMed  Google Scholar 

  2. Matsuoka YJ, Okubo R, Shimizu Y et al (2020) Developing the structure of Japan’s cancer survivorship guidelines using an expert panel and modified Delphi method. J Cancer Surviv 14:273–283

    Article  PubMed  Google Scholar 

  3. Ministry of Health, Labour and Welfare in Japan (2021) Summary of Vital Statistics—Trends in leading causes of death. https://www.mhlw.go.jp/english/database/db-hw/populate/dl/E03.pdf. Accessed 3 March 2023

  4. National Cancer Center in Japan (2007) Cancer Statistics in Japan ‘07—Cancer Prevalence Estimates (in Japanese). https://ganjoho.jp/data/reg_stat/statistics/brochure/2007/FIG21.PDF. Accessed 3 March 2023

  5. Bluethmann SM, Mariotto AB, Rowland JH (2016) Anticipating the ‘Silver Tsunami’: prevalence trajectories and co-morbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 25:1029–1036

    Article  PubMed  PubMed Central  Google Scholar 

  6. Cortaredona S, Ventelou B (2017) The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases. BMC Med 15:216

    Article  PubMed  PubMed Central  Google Scholar 

  7. Essa H, Dobson R, Wright D et al (2020) Hypertension management in cardio-oncology. J Hum Hypertens 34:673–681

    Article  PubMed  PubMed Central  Google Scholar 

  8. Muto S, Matsubara T, Inoue T et al (2023) Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol. https://doi.org/10.1007/s10147-023-02372-4

  9. Rosner MH, Jhaveri KD, McMahon BA et al (2021) Onconephrology: the intersections between the kidney and cancer. CA Cancer J Clin 71:47–77

    Article  PubMed  Google Scholar 

  10. Latcha S, Jaimes EA, Patil S et al (2016) Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol 11:1173–1179

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Leppert JT, Lamberts RW, Thomas IC et al (2018) Incident CKD after radical or partial nephrectomy. J Am Soc Nephrol 29:207–216

    Article  PubMed  Google Scholar 

  12. Aguilar Palacios D, Wilson B, Ascha M et al (2021) New baseline renal function after radical or partial nephrectomy: a simple and accurate predictive model. J Urol 205:1310–1320

    Article  PubMed  Google Scholar 

  13. Tachibana H, Omae K, Ishihara H et al (2022) Validation of predictive model for new baseline renal function after robot-assisted partial nephrectomy or radical nephrectomy in Japanese patients. J Endourol 36:745–751

    Article  PubMed  Google Scholar 

  14. Naganuma T, Takemoto Y, Maeda S et al (2012) Chronic kidney disease in patients with ileal conduit urinary diversion. Exp Ther Med 4:962–966

    Article  PubMed  PubMed Central  Google Scholar 

  15. Vejlgaard M, Maibom SL, Stroomberg HV et al (2022) Long-term renal function following radical cystectomy for bladder cancer. Urology 160:147–153

    Article  PubMed  Google Scholar 

  16. Jiang C, Deng L, Karr MA et al (2022) Chronic comorbid conditions among adult cancer survivors in the United States: results from the National Health Interview Survey, 2002–2018. Cancer 128:828–838

    Article  PubMed  Google Scholar 

  17. Petrova D, Catena A, Rodríguez-Barranco M et al (2021) Physical comorbidities and depression in recent and long-term adult cancer survivors: NHANES 2007–2018. Cancers (Basel) 13:3368

    Article  PubMed  Google Scholar 

  18. Shin HY, Linton JA, Shim JY et al (2015) Cancer survivors aged 40 years or elder are associated with high risk of chronic kidney disease: the 2010–2012 Korean National Health and Nutrition Examination Survey. Asian Pac J Cancer Prev 16:1355–1360

    Article  PubMed  Google Scholar 

  19. Takeuchi M, Shinkawa K, Yanagita M et al (2021) Prevalence, recognition and management of chronic kidney disease in Japan: population-based estimate using a healthcare database with routine health checkup data. Clin Kidney J 14:2197–2202

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Oeffinger KC, Mertens AC, Sklar CA et al (2016) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 355:1572–1582

    Article  Google Scholar 

  21. Knijnenburg SL, Jaspers MW, van der Pal HJ et al (2012) Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol 7:1416–1427

    Article  PubMed  PubMed Central  Google Scholar 

  22. Green DM, Wang M, Krasin M et al (2021) Kidney function after treatment for childhood cancer: a report from the St. Jude Lifetime Cohort Study. J Am Soc Nephrol 32:983–993

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. McMahon KR, Harel-Sterling M, Pizzi M et al (2018) Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study. Pediatr Nephrol 33:2311–2320

    Article  PubMed  Google Scholar 

  24. McMahon KR, Rassekh SR, Schultz KR et al (2020) Epidemiologic characteristics of acute kidney injury during cisplatin infusions in children treated for cancer. JAMA Netw Open. 3:e203639

    Article  PubMed  PubMed Central  Google Scholar 

  25. Dekkers IA, Blijdorp K, Cransberg K et al (2013) Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol 8:922–929

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Skinner R, Pearson AD, English MW et al (1998) Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77:1677–1682

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Skinner R, Parry A, Price L et al (2009) Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer 45:3213–3219

    Article  CAS  PubMed  Google Scholar 

  28. Skinner R, Cotterill SJ, Stevens MC (2000) Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children’s Cancer Study Group. Br J Cancer 82:1636–1645

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Nada A, Jetton JG (2022) Pediatric onco-nephrology: time to spread the Word-Part II: long-term kidney outcomes in survivors of childhood malignancy and malignancy after kidney transplant. Pediatr Nephrol 37:1285–1300

    Article  PubMed  Google Scholar 

  30. Mulder RL, Knijnenburg SL, Geskus RB et al (2013) Glomerular function time trends in long-term survivors of childhood cancer: a longitudinal study. Cancer Epidemiol Biomarkers Prev 22:1736–1746

    Article  CAS  PubMed  Google Scholar 

  31. Interiano RB, Delos Santos N, Huang S et al (2015) Renal function in survivors of nonsyndromic Wilms tumor treated with unilateral radical nephrectomy. Cancer 121:2449–2456

    Article  PubMed  Google Scholar 

  32. Cohen EP, Pais P, Moulder JE (2010) Chronic kidney disease after hematopoietic stem cell transplantation. Semin Nephrol 30:627–634

    Article  PubMed  PubMed Central  Google Scholar 

  33. Bolling T, Willich N, Ernst I (2010) Late effects of abdominal irradiation in children: a review of the literature. Anticancer Res 30:227–231

    PubMed  Google Scholar 

  34. Matsuoka YJ, Okubo R, Shimizu Y et al (2020) Developing the structure of Japan’s cancer survivorship guidelines using an expert panel and modified Delphi method. J Cancer Surviv 14:273–283

    Article  PubMed  Google Scholar 

  35. Chao C, Bhatia S, Xu L et al (2020) Chronic comorbidities among survivors of adolescent and young adult cancer. J Clin Oncol 38:3161–3174

    Article  PubMed  PubMed Central  Google Scholar 

  36. Japanese Society of Nephrology (2018) Evidence-based Clinical Practice Guidelines for the treatment of CKD (in Japanese). https://jsn.or.jp/medic/guideline/. Accessed May 2023

  37. Rowland JH, Bellizzi KM (2014) Cancer survivorship issues: life after treatment and implications for an aging population. J Clin Oncol 32:2662–2668

    Article  PubMed  PubMed Central  Google Scholar 

  38. Henderson TO, Ness KK, Cohen HJ (2014) Accelerated aging among cancer survivors: from pediatrics to geriatrics. Am Soc Clin Oncol Educ Book e423–e430

  39. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  CAS  PubMed  Google Scholar 

  40. Guida JL, Ahles TM, Belsky D et al (2019) Measuring aging and identifying aging phenotypes in cancer survivors. J Natl Cancer Inst 111:1245–1254

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4:798–804

    Article  PubMed  PubMed Central  Google Scholar 

  42. Cespedes Feliciano EM, Kroenke C et al (2017) Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: Results from the C SCANS Study. JAMA Oncol 3:e172319

    Article  PubMed Central  Google Scholar 

  43. Hsu CY, Chinchilli VM, Coca S et al (2020) Post-acute kidney injury proteinuria and subsequent kidney disease progression; The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Study. JAMA Intern Med 180:402–410

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Uchida D, Kawarazaki H, Shibagaki Y et al (2015) Underestimating chronic kidney disease without serum creatinine as a screening tool in the general Japanese population. Clin Exp Nephrol 19:474–480

    Article  CAS  PubMed  Google Scholar 

  45. Inker LA, Astor BC, Fox CH et al (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63:713–735

    Article  PubMed  Google Scholar 

  46. Uhlig K, Boyd C (2011) Guideline for the older adult with CKD. Am J Kidney Dis 58:162–165

    Article  PubMed  Google Scholar 

  47. Saver JL, Lewis RJ (2019) Number needed to treat: conveying the likelihood of a therapeutic effect. JAMA 321:798–799

    Article  PubMed  Google Scholar 

  48. The SPRINT Research Group (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116

    Article  PubMed Central  Google Scholar 

  49. Working Group for Dietary Therapy in CKD with Sarcopenia/frailty (in Japanese) (2019) Recommendation for dietary therapy in predialysis CKD with sarcopenia/frailty. J Jpn Soc Nephrol 61:525–556

    Google Scholar 

  50. Neuen BL, Ohkuma T, Neal B et al (2019) Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program. J Am Soc Nephrol 30:2229–2242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Chinnadurai R, Flanagan E, Jayson GC et al (2019) Cancer patterns and association with mortality and renal outcomes in non- dialysis dependent chronic kidney disease: a matched cohort study. BMC Nephrol 20:380

    Article  PubMed  PubMed Central  Google Scholar 

  52. Arnold M, Rutherford MJ, Bardot A et al (2019) Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 20:1493–1505

    Article  PubMed  PubMed Central  Google Scholar 

  53. Brattström C, Granath F, Edgren G et al (2013) Overall and cause-specific mortality in transplant recipients with a pretransplantation cancer history. Transplantation 96:297–305

    Article  PubMed  Google Scholar 

  54. Boissier R, Hevia V, Bruins HM et al (2018) The risk of tumour recurrence in patients undergoing renal transplantation for end-stage renal disease after previous treatment for a urological cancer: a systematic review. Eur Urol 73:94–108

    Article  PubMed  Google Scholar 

  55. Kasiske BL, Cangro CB, Hariharan S et al (2001) The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 1(Suppl 2):3–95

    PubMed  Google Scholar 

  56. Knoll G, Cockfield S, Blydt-Hansen T et al (2005) Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ 173(10):S1–S25

    Article  PubMed  PubMed Central  Google Scholar 

  57. European Renal Best Practice Transplantation Guideline Development Group (2013) ERBP guideline on the management and evaluation of the kidney donor and recipient. Nephrol Dial Transplant 28(Suppl 2):ii1–ii71

    Google Scholar 

  58. Campbell S, Pilmore H, Gracey D et al (2013) KHA-CARI guideline: recipient assessment for transplantation. Nephrology 18:455–462

    Article  PubMed  Google Scholar 

  59. Sprangers B, Nair V, Launay-Vacher V et al (2018) Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. Clin Kidney J 11:315–329

    Article  CAS  PubMed  Google Scholar 

  60. Penn I, Hammond W, Brettschneider L et al (1969) Malignant lymphomas in transplantation patients. Transplant Proc 1:106–112

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Jeong S, Lee HS, Kong SG et al (2020) Incidence of malignancy and related mortality after kidney transplantation: a nationwide, population-based cohort study in Korea. Sci Rep 10:21398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Vajdic CM, McDonald SP, McCredie MR et al (2006) Cancer incidence before and after kidney transplantation. JAMA 296:2823–2831

    Article  CAS  PubMed  Google Scholar 

  63. Imamura R, Nakazawa S, Yamanaka K et al (2021) Cumulative cancer incidence and mortality after kidney transplantation in Japan: a long-term multicenter cohort study. Cancer Med 10:2205–2215

    Article  CAS  PubMed  Google Scholar 

  64. Blosser CD, Haber G, Engels EA (2021) Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period. Kidney Int 99:1430–1438

    Article  PubMed  Google Scholar 

  65. Butler AM, Olshan AF, Kshirsagar AV et al (2015) Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996–2009. Am J Kidney Dis 65:763–772

    Article  PubMed  PubMed Central  Google Scholar 

  66. Cheung CY, Chan GC, Chan SK et al (2016) Cancer incidence and mortality in chronic dialysis population: a multicenter cohort study. Am J Nephrol 43:153–159

    Article  PubMed  Google Scholar 

  67. Malachi T, Zevin D, Gafter U et al (1993) DNA repair and recovery of RNA synthesis in uremic patients. Kidney Int 44:385–389

    Article  CAS  PubMed  Google Scholar 

  68. Rangel-López A, Paniagua-Medina ME, Urbán-Reyes M et al (2013) Genetic damage in patients with chronic kidney disease, peritoneal dialysis and haemodialysis: a comparative study. Mutagenesis 28:219–225

    Article  PubMed  PubMed Central  Google Scholar 

  69. Akizawa T, Kinugasa E, Koshikawa S (1994) Increased risk of malignancy and blood-membrane interactions in uraemic patients. Nephrol Dial Transplant 9(Suppl 2):162–164

    PubMed  Google Scholar 

  70. Japanese Society for Dialysis Therapy (2021) Current status of dialysis therapy of Japan (as of Dec 31, 2020) (in Japanese). https://docs.jsdt.or.jp/overview/index2021.html. Accessed May 2023

Download references

Acknowledgements

This article is the secondary publication from Japanese version by Japanese Society of nephrology (JSN), Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and The Japanese society of Nephrology and pharmacotherapy (JSNP) that was published Lifescience Publishers Co Ltd, Tokyo, Japan, with permission. We greatly thank other guideline committee members for peer reviews and external review teams from JSN, JSCO, JSMO, JSNP, and the Japanese Society for Dialysis Therapy for their suggestive advice and cooperation. We also thank Toshio Morizane (Japan Council for Quality Health Care), Takeo Nakayama (Department of Health Informatics, School of Public Health, Kyoto University Graduate School of Medicine), and Shigeo Horie (Department of Urology, Juntendo University Faculty of Medicine) for an advisor, Naoki Kashihara (Kawasaki Medical School), Mototsugu Oya (Keio University School of Medicine), Hirokazu Okada (Saitama Medical University), and Masaomi Nangaku (The University of Tokyo) for supervisors of the guideline, Takashi Yokoo (JSN academic committee chairman, Jikei University School of Medicine) and Kengo Furuichi (JSN academic committee vice chairman, Kanazawa Medical University School of Medicine) for observers, Eiichiro Kanda (Kawasaki Medical School) and Takaaki Suzuki (Nara Medical University Library) for systematic literature searching, Hitoshi Watanabe (Lifescience, Co. Ltd.) for editing the Japanese version of the guidelines, office staffs of JSN, JSCO, JSMO, and JSNP, and Yasuhiro Komatsu (Gunma University) for helpful supports.

Author information

Author notes

  1. Kenji Ishikura, Kenji Omae, and Sho Sasaki have equally contributed to this work.

Authors and Affiliations

  1. Department of Pediatrics, Kitasato University School of Medicine, Kawasaki, Japan

    Kenji Ishikura & Yusuke Okuda

  2. Department of Innovative Research and Education for Clinicians and Trainees, Fukushima Medical University Hospital, Fukushima, Japan

    Kenji Omae

  3. Section of Education for Clinical Research, Kyoto University Hospital, Kyoto, Japan

    Sho Sasaki

  4. Division of Nephrology and Hypertension, Department of Internal Medicine, Saint Marianna University School of Medicine, Kanagawa, Japan

    Yugo Shibagaki

  5. Department of Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan

    Satoko Ichioka

  6. Division of Nephrology, Inagi Municipal Hospital, Tokyo, Japan

    Kenichiro Koitabashi

  7. Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan

    Koichi Suyama

  8. Department of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan

    Takuro Mizukami

  9. Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan

    Chihiro Kondoh

  10. Department of Academic Education, I & H Co., Ltd, Ashiya, Japan

    Sumio Hirata

  11. Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Takeshi Matsubara & Motoko Yanagita

  12. Department of Nephrology, Tokyo Women’s Medical University, Tokyo, Japan

    Junichi Hoshino

  13. Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan

    Motoko Yanagita

Authors
  1. Kenji Ishikura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenji Omae
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sho Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yugo Shibagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satoko Ichioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yusuke Okuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenichiro Koitabashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Koichi Suyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takuro Mizukami
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Chihiro Kondoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sumio Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Takeshi Matsubara
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Junichi Hoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Motoko Yanagita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yugo Shibagaki.

Ethics declarations

Conflict of interest

Y.S has received honoraria from AstraZeneca, Kyowa Kirin Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., and research fundings from Bayer AG, Baxter, Kyowa Kirin Co., Ltd., and Teijin. T. M has received a research funding from Eli Lilly Japan K.K. J.H has received honoraria from Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma, Ono Pharm, AstraZeneca and Astellas Pharma Inc, and a research grant from Otsuka Pharmaceutical Co., Ltd. M.Y has received honoraria from Astellas Pharma Inc, AstraZeneca, Kyowa Kirin Co., Ltd., Chugai-Pharmaceutical Co., Ltd., Bayer AG, and Mitsubishi Tanabe Pharma, and research grants from Mitsubishi Tanabe Pharma, Boehringer Ingelheim International GmbH, and scholarship donations from Kyowa Kirin Co., Ltd., Chugai-Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma. The other authors declare no potential conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ishikura, K., Omae, K., Sasaki, S. et al. Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022. Int J Clin Oncol 28, 1333–1342 (2023). https://doi.org/10.1007/s10147-023-02375-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-023-02375-1

Keywords

Search

Navigation